Evidence map›Paper›PMID 33269530›Full record

Trial reportDiabetes, obesity & metabolism2021

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.

Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon, Alicja Wizert, Dorthe Skovgaard

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03842202. Cited by 191 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 13 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03842202 phase1completed

Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity

Ran2019Enrolled72Registered outcomes10Posted comparisons0ConditionsObesity, OverweightArmsPlacebo, semaglutide
Open the trial in the graph
NCT07234916 naenrolling by invitationnot on this mapstarted 2025, after this paper: background citation

The Impact of Multivitamin Supplementation on Micronutrient Levels in GLP-1 Users: A Randomized, Double-Blind, Placebo-Controlled Trial

TypeinterventionalSponsorErasmus Medical CenterRan2025 to 2027Enrolled246ConditionsWeight Loss, Nutritional Deficiencies, GLP - 1, Obese PatientsArmsMultivitamin Supplementation, Placebo
3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 13 syntheses or guidelines pooled it, 359 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Once-Weekly Semaglutide in Adolescents with Obesity.The New England journal of medicine · 2022 · on this map
    Trial
  20. Trial

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Martin FriedrichsenNovo Nordisk A/S, Søborg, Denmark.ORCID 0000-0003-3383-9593
Astrid BreitschaftParexel International GmbH, Berlin, Germany.
Sayeh TadayonNovo Nordisk A/S, Søborg, Denmark.
Alicja WizertNovo Nordisk A/S, Søborg, Denmark.
Dorthe SkovgaardNovo Nordisk A/S, Søborg, Denmark.
Novo Nordisk (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the effects of once-weekly subcutaneous (s.c.) semaglutide 2.4 mg on gastric emptying, appetite, and energy intake in adults with obesity. MATERIALS AND

methodsA double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks. Gastric emptying was assessed using paracetamol absorption following a standardized breakfast. Participant-reported appetite ratings and Control of Eating Questionnaire (CoEQ) responses were assessed, and energy intake was measured during ad libitum lunch.

resultsThe area under the concentration-time curve (AUC) for paracetamol 0 to 5 hours after a standardized meal (AUC

conclusionsIn adults with obesity, once-weekly s.c. semaglutide 2.4 mg suppressed appetite, improved control of eating, and reduced food cravings, ad libitum energy intake and body weight versus placebo. There was no evidence of delayed gastric emptying at week 20, assessed indirectly via paracetamol absorption.

Indexed as

AppetiteGastric EmptyingAdultDouble-Blind MethodEnergy IntakeGlucagon-Like PeptidesHumansObesityProspective StudiesSemaglutideGlucagon-Like PeptidesSemaglutideappetitecontrol of eatingenergy intakefood cravinggastric emptyingGLP-1 analogueglucagon-like peptide-1obesityrandomized trialsemaglutide

Identifiers

PMID33269530
PMCPMC7898914
OpenAlexW3109063372

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.